Scientific Publications
ADPD 2023 Poster: Impact of the Highly Selective D1-Like Partial Dopamine Agonist Tavapadon on Daytime Sleepiness: Evidence From a Phase 2 Clinical Trial
Mar 28, 2023
Efficacy of CV-0000042, a Novel M4 Receptor Full Agonist, and CV-0000071, a Novel M4 Receptor Partial Agonist, in Preclinical In Vivo Models of Psychosis
Nov 13, 2022
Binding and Signal Profiling of Full and Partial M4 Agonists
Nov 13, 2022
Efficacy of Subtype-Selective, Full vs Partial M4 Muscarinic Receptor Agonists in Modulating Amphetamine-Induced Brain Activity Assessed by Functional MRI (fMRI) in Rats
Nov 13, 2022
IARPD 2022 Poster - Setting the TEMPO: A Phase 3 Program to Investigate Tavapadon, a Selective D1/D5 Partial Agonist, for Parkinson’s Disease
May 13, 2022
SIRS 2022 Presentation – Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia
Apr 08, 2022
AAN 2022 Poster - Levodopa and Dopamine Agonist Medication Utilization among Patients with Parkinson’s Disease Enrolled in Commercial and Medicare Advantage Part D Health Plans
Apr 05, 2022
AAN 2022 Presentation - Darigabat: pronounced antiepileptic activity in the mesial temporal lobe mouse model of drug-resistant focal epilepsy
Apr 05, 2022
AAN 2022 Poster - Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic
Apr 05, 2022
AAN 2022 Poster - Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Early Phase Clinical Studies
Apr 05, 2022